MDT

85.26

-0.95%↓

A

120.85

-0.66%↓

VEEV

168.97

+0.64%↑

HQY

86.11

+0.21%↑

NEOG

9.63

+1.37%↑

MDT

85.26

-0.95%↓

A

120.85

-0.66%↓

VEEV

168.97

+0.64%↑

HQY

86.11

+0.21%↑

NEOG

9.63

+1.37%↑

MDT

85.26

-0.95%↓

A

120.85

-0.66%↓

VEEV

168.97

+0.64%↑

HQY

86.11

+0.21%↑

NEOG

9.63

+1.37%↑

MDT

85.26

-0.95%↓

A

120.85

-0.66%↓

VEEV

168.97

+0.64%↑

HQY

86.11

+0.21%↑

NEOG

9.63

+1.37%↑

MDT

85.26

-0.95%↓

A

120.85

-0.66%↓

VEEV

168.97

+0.64%↑

HQY

86.11

+0.21%↑

NEOG

9.63

+1.37%↑

Search

Simulations Plus Inc

Suletud

SektorTervishoid

14.99 5.05

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

14.15

Max

14.99

Põhinäitajad

By Trading Economics

Sissetulek

3.9M

4.5M

Müük

5.9M

24M

Aktsiakasum

0.35

Dividenditootlus

0.48

Kasumimarginaal

18.669

Töötajad

212

EBITDA

4.9M

7.2M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+63.54% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

0.48%

2.38%

Järgmine tulemuste avaldamine

13. juuli 2026

Turustatistika

By TradingEconomics

Turukapital

11M

262M

Eelmine avamishind

9.94

Eelmine sulgemishind

14.99

Uudiste sentiment

By Acuity

20%

80%

55 / 348 Pingereas Healthcare

Simulations Plus Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

20. apr 2026, 23:49 UTC

Uudisväärsed sündmused

New Zealand 1Q Inflation Higher Than Expected

20. apr 2026, 23:10 UTC

Kuumad aktsiad

Stocks to Watch: Amazon, Alaska Air Group, BridgeBio Oncology, AXT

20. apr 2026, 22:53 UTC

Suurimad hinnamuutused turgudel

BridgeBio Oncology Shares Rise After FDA Fast-Tracks Pancreatic Cancer Treatment

20. apr 2026, 23:45 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

20. apr 2026, 23:44 UTC

Market Talk

Gold Consolidates as End of Cease-Fire Looms -- Market Talk

20. apr 2026, 23:39 UTC

Market Talk

Rio Tinto Posts Strong Start to Year -- Market Talk

20. apr 2026, 23:30 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20. apr 2026, 23:30 UTC

Market Talk

Global Equities Roundup: Market Talk

20. apr 2026, 23:30 UTC

Market Talk

Super Retail's Earnings Outlook Less Rosy -- Market Talk

20. apr 2026, 23:09 UTC

Market Talk

Viva Energy's Refinery Fire More Benign Than Jefferies Thought -- Market Talk

20. apr 2026, 22:31 UTC

Omandamised, ülevõtmised, äriostud

Anthropic, Amazon Tighten Bond in $5 Billion Investment and Computing Deal -- WSJ

20. apr 2026, 22:26 UTC

Omandamised, ülevõtmised, äriostud

West African Resources Says Sanbrado, Toega Operations Not Subject to Govt Request for Additional Participation

20. apr 2026, 22:25 UTC

Omandamised, ülevõtmised, äriostud

West African Resources Plans to Distribute Cash Proceeds to Shareholders Via Special Dividend

20. apr 2026, 22:25 UTC

Omandamised, ülevõtmised, äriostud

West African Resources Aims for Acquisition to Be Completed by End-2026

20. apr 2026, 22:25 UTC

Omandamised, ülevõtmised, äriostud

West African Resources Says to Work Cooperatively With Govt to Finalize Deal Terms

20. apr 2026, 22:25 UTC

Omandamised, ülevõtmised, äriostud

West African Resources Says Acquisition Would Be for A$175 Million

20. apr 2026, 22:24 UTC

Omandamised, ülevõtmised, äriostud

West African Resources Says Burkina Faso Govt Issues Decree to Acquire 25% of Kiaka

20. apr 2026, 22:15 UTC

Omandamised, ülevõtmised, äriostud

Anthropic, Amazon Tighten Bond in $5 Billion Investment and Computing Deal -- WSJ

20. apr 2026, 22:01 UTC

Omandamised, ülevõtmised, äriostud

Amazon Invests $5B in Anthropic Amid Expanded Collaboration

20. apr 2026, 21:38 UTC

Market Talk

Apple's New CEO Will Face Immediate Pressure on AI Strategy -- Market Talk

20. apr 2026, 21:33 UTC

Omandamised, ülevõtmised, äriostud

Uber Expands Stake In Lucid for Robo-Taxis. This Is How Tesla's Stock Is Responding. -- Barrons.com

20. apr 2026, 21:24 UTC

Market Talk

Apple's CEO Change Timing Will Garner Mixed Reaction, Analyst Says -- Market Talk

20. apr 2026, 21:24 UTC

Market Talk

Global Equities Roundup: Market Talk

20. apr 2026, 21:13 UTC

Tulu

Alaska Air: Expansion of Card Portfolio Expected to Accelerate Loyalty Platform Beyond Incremental $150M Profit Outlined in Alaska Accelerate Strategy

20. apr 2026, 21:10 UTC

Tulu

Alaska Air to Move Toward a Single Issuer for Atmos Rewards Credit Cards

20. apr 2026, 21:09 UTC

Tulu

Alaska Air Sees 2Q Capacity Up About 1% Year-Over-Year, Down Nearly a Point From Original Views, on 'Proactive Trimming' of May and June Capacity

20. apr 2026, 21:08 UTC

Tulu

Alaska Air 'Continues to Operate From a Position of Strength,' With Healthy Balance Sheet, Strong Liquidity, About $20B in Unencumbered Assets

20. apr 2026, 21:07 UTC

Tulu

Alaska Air: Taken Together, Rev, Cost and Fuel Assumptions Result in 2Q Adjusted Loss Per Share Estimate of About $1

20. apr 2026, 21:05 UTC

Tulu

Alaska Air: This Assumption Adds About $600M of Expense to 2Q, Equivalent to EPS Headwind of $3.60

20. apr 2026, 21:05 UTC

Tulu

Alaska Air Expects 2Q Fuel Cost to Average About $4.50 Based on Forward Curve Today

Võrdlus sarnastega

Hinnamuutus

Simulations Plus Inc Prognoos

Hinnasiht

By TipRanks

63.54% tõus

12 kuu keskmine prognoos

Keskmine 23.5 USD  63.54%

Kõrge 31 USD

Madal 16 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Simulations Plus Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

4 ratings

2

Osta

2

Hoia

0

Müü

Sentiment

By Acuity

55 / 348 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat